Analysts’ Weekly Ratings Updates for Atara Biotherapeutics (ATRA)

Atara Biotherapeutics (NASDAQ: ATRA) has recently received a number of price target changes and ratings updates:

  • 9/11/2017 – Atara Biotherapeutics had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $47.00 price target on the stock.
  • 9/1/2017 – Atara Biotherapeutics was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.
  • 8/31/2017 – Atara Biotherapeutics had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $30.00 price target on the stock.
  • 8/28/2017 – Atara Biotherapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. “
  • 8/22/2017 – Atara Biotherapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/22/2017 – Atara Biotherapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. They now have a $15.00 price target on the stock. According to Zacks, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. “
  • 8/7/2017 – Atara Biotherapeutics was given a new $47.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 8/1/2017 – Atara Biotherapeutics was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) opened at 15.15 on Wednesday. Atara Biotherapeutics, Inc. has a 12-month low of $11.80 and a 12-month high of $23.00. The firm’s market cap is $462.97 million. The firm’s 50-day moving average price is $14.74 and its 200 day moving average price is $15.87.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.05). Analysts forecast that Atara Biotherapeutics, Inc. will post ($3.89) earnings per share for the current fiscal year.

In other Atara Biotherapeutics news, EVP Mitchall G. Clark sold 3,021 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $14.33, for a total value of $43,290.93. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Christopher Haqq sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $12.65, for a total transaction of $75,900.00. Following the completion of the sale, the executive vice president now owns 368,080 shares in the company, valued at approximately $4,656,212. The disclosure for this sale can be found here. Insiders sold 49,509 shares of company stock worth $726,242 in the last 90 days. Company insiders own 16.10% of the company’s stock.

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Receive News & Ratings for Atara Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.